TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
GOSS

Gossamer Bio Inc

Healthcare · Biotechnology

9.50$ -9.0% vs. previous close Closing price · As of: Nov 2, 2026

Ownership

Ownership Structure

Who owns Gossamer Bio Inc (GOSS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 62.5% of the shares are freely tradable; institutional investors hold 75.2%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 75.2%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 1.7%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 62.5%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 20.5%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 6Mio.

Largest Shareholders

Institutions

Institutions GOSS
Name Stake (%) Shares Change (%) Date
D. E. Shaw & Co LP 8.37 40,959,285 +10,417.7 06/30/2026
DeepCurrents Investment Group LLC 7.70 37,665,073 +0.0 06/30/2026
Context Capital Management LLC 5.92 28,946,459 +0.0 06/30/2026
Worth Venture Partners, LLC 5.11 25,017,881 +0.0 06/30/2026
Kalehua Capital Management LLC 4.56 22,298,726 +25.9 06/30/2026
AQR Capital Management LLC 3.19 15,629,993 +54.3 06/30/2026
GSA Capital Partners LLP 3.06 14,986,947 +360.5 06/30/2026
Wolverine Asset Management LLC 2.64 12,894,746 +0.0 06/30/2026
Renaissance Technologies Corp 2.38 11,629,896 +854.9 06/30/2026
Vanguard Capital Management, LLC 1.92 9,416,023 +0.2 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?